315 related articles for article (PubMed ID: 31242158)
1. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
[TBL] [Abstract][Full Text] [Related]
2. Impact of meningococcal group B OMV vaccines, beyond their brief.
Petousis-Harris H
Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
[TBL] [Abstract][Full Text] [Related]
3. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
Sierra-González VG
MEDICC Rev; 2019 Oct; 21(4):19-27. PubMed ID: 32335565
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
7. [Meningococcus B serosubtypes causing invasive disease in Cantabria [Spain] and agreement with the Cuban vaccine strain].
González de Aledo A; Viloria L
Gac Sanit; 2004; 18(1):45-9. PubMed ID: 14980172
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
9. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
[TBL] [Abstract][Full Text] [Related]
10. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
11. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.
Climent Y; Yero D; Martinez I; Martín A; Jolley KA; Sotolongo F; Maiden MC; Urwin R; Pajón R
J Clin Microbiol; 2010 Mar; 48(3):802-10. PubMed ID: 20042619
[TBL] [Abstract][Full Text] [Related]
12. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
Masforrol Y; Gil J; García D; Noda J; Ramos Y; Betancourt L; Guirola O; González S; Acevedo B; Besada V; Reyes O; González LJ
Hum Vaccin Immunother; 2017 Nov; 13(11):2548-2560. PubMed ID: 29083947
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in vaccines to prevent meningococcal serogroup B infections.
Vermont CL; van den Dobbelsteen GP; de Groot R
Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
[TBL] [Abstract][Full Text] [Related]
15. [Characterization of Neisseria meningitidis strains isolated from carriers in Cuba during 20 years].
Martínez Motas I; Sierra González G; Núñez Gutiérrez N; Izquierdo Pérez L; Climent Ruíz Y; Mirabal Sosa M
Rev Cubana Med Trop; 2006; 58(2):124-33. PubMed ID: 23427430
[TBL] [Abstract][Full Text] [Related]
16. Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?
Lucidarme J; Lekshmi A; Parikh SR; Bray JE; Hill DM; Bratcher HB; Gray SJ; Carr AD; Jolley KA; Findlow J; Campbell H; Ladhani SN; Ramsay ME; Maiden MCJ; Borrow R
J Infect; 2017 Aug; 75(2):95-103. PubMed ID: 28579305
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
18. Neisseria meningitidis serogroup B: laboratory correlates of protection.
Vermont C; van den Dobbelsteen G
FEMS Immunol Med Microbiol; 2002 Oct; 34(2):89-96. PubMed ID: 12381458
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
